Protagonist Therapeutics Inc PTGX

NAS: PTGX | ISIN: US74366E1029 14/11/2024

41,04 USD (-3,82%)

(-3,82%) 14/11/2024

Grafiek Protagonist Therapeutics Inc

Grafiek Protagonist Therapeutics Inc

1 dag1d -3,82%
1 week1w -11,23%
1 maand1m -13,85%
3 maanden3m 1,11%
6 maanden6m 30,41%
1 jaar1j 151,93%
5 jaar5j 284,45%

Protagonist Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

27 juni 2024 · Protagonist Therapeutics Set to Join S&P SmallCap 600 · Persbericht

12 mei 2023 · Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 · Persbericht

11 mei 2023 · Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference · Persbericht

11 mei 2023 · Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association · Persbericht

4 mei 2023 · Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

7 maart 2023 · Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis · Persbericht

21 december 2022 · Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2022 · Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit · Persbericht

16 november 2022 · Protagonist Therapeutics Reports Granting of Inducement Award · Persbericht

8 november 2022 · Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

Profiel Protagonist Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 99

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe